Treatment of chronic inflammatory diseases with biologic agents: Opportunities and risks for the elderly

被引：9

作者：

Diaz-Borjon, Alejandro ^{[1
]}

Weyand, Cornelia M. ^{[1
]}

Goronzy, Jorg J. ^{[1
]}

机构：

[1] Emory Univ, Sch Med, Kathleen B & Mason I Lowance Ctr Human Immunol, Dept Med, Atlanta, GA 30322 USA

来源：

EXPERIMENTAL GERONTOLOGY | 2006年 / 41卷 / 12期

关键词：

biologic agents; autoimmune rheumatic disease; B cells; T cells; elderly;

D O I：

10.1016/j.exger.2006.10.010

中图分类号：

R592 [老年病学]; C [社会科学总论];

学科分类号：

03 [法学]; 0303 [社会学]; 100203 [老年医学];

摘要：

The treatment armamentarium in rheumatic inflammatory diseases has drastically increased in the last years. Earlier uses of conventional disease-modifying antirheumatic drugs (DMARDs), along with the arrival of newer therapies including the so-called "biologic" agents, have provided better long-term outcomes for patients suffering from these illnesses. Biologic agents have shown efficacy for several diseases and failed in others. Due to a high prevalence of some of these diseases in the elderly population, this age group may also benefit, although treatment will have to be tailored to its special needs. In this mini review, we will discuss the use of these medications in rheumatic diseases with a significant prevalence in the elderly, their proven and potential uses, and the considerations that need to be taken into account when using them in this population. (c) 2006 Elsevier Inc. All rights reserved.

引用

收藏

页码：1250 / 1255

页数：6

相关论文

共 28 条

[1]

Rituximab therapy for de novo mixed cryoglobulinemia in renal transplant patients [J].

Basse, G ;

Ribes, D ;

Kamar, N ;

Mehrenberger, M ;

Esposito, L ;

Guitard, J ;

Lavayssière, L ;

Oksman, F ;

Dur, D ;

Rostaing, L .

TRANSPLANTATION, 2005, 80 (11) :1560-1564

[2]

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies - Systematic review and meta-analysis of rare harmful effects in randomized controlled trials [J].

Bongartz, T ;

Sutton, AJ ;

Sweeting, MJ ;

Buchan, I ;

Matteson, EL ;

Montori, V .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (19) :2275-2285

[3]

The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment [J].

Breedveld, FC ;

Weisman, MH ;

Kavanaugh, AF ;

Cohen, SB ;

Pavelka, K ;

van Vollenhoven, R ;

Sharp, J ;

Perez, JL ;

Spencer-Green, GT .

ARTHRITIS AND RHEUMATISM, 2006, 54 (01) :26-37

[4]

Cai FZJ, 2006, J RHEUMATOL, V33, P1197

[5]

Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies [J].

Calabrese, L. H. ;

Zein, N. N. ;

Vassilopoulos, D. .

ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (08) :983-989

[6]

Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection [J].

Calabrese, LH ;

Zein, N ;

Vassilopoulos, D .

ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 :18-24

[7]

B cells and aging: gauging the interplay of generative, selective, and homeostatic events [J].

Cancro, MP .

IMMUNOLOGICAL REVIEWS, 2005, 205 :48-59

[8]

Recombinant human tumor necrosis factor receptor, (etanercept) for treating ankylosing spondylitis - A randomized, controlled trial [J].

Davis, JC ;

van der Heijde, D ;

Braun, J ;

Dougados, M ;

Cush, J ;

Clegg, DO ;

Kivitz, A ;

Fleischmann, R ;

Inman, R ;

Tsuji, W .

ARTHRITIS AND RHEUMATISM, 2003, 48 (11) :3230-3236

[9]

Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients [J].

Efthimiou, P. ;

Schwartzman, S. ;

Kagen, L. J. .

ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (09) :1233-1236

[10]

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment - Results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial [J].

Emery, P ;

Fleischmann, R ;

Filipowicz-Sosnowska, A ;

Schechtman, J ;

Szczepanski, L ;

Kavanaugh, A ;

Racewicz, AJ ;

Van Vollenhoven, RF ;

Li, NF ;

Agarwal, S ;

Hessey, EW ;

Shaw, TM .

ARTHRITIS AND RHEUMATISM, 2006, 54 (05) :1390-1400